These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33722440)

  • 21. Finding the sweet spot in managing diabetes with coronary artery disease and chronic kidney disease: Pharmacotherapy pearls with a focus on sodium-glucose cotransporter-2 inhibitors.
    Trischuk T; Laubscher T; Regier L
    Can Fam Physician; 2020 May; 66(5):341-346. PubMed ID: 32404456
    [No Abstract]   [Full Text] [Related]  

  • 22. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
    Karangelis D; Mazer CD; Stakos D; Tzifa A; Loggos S; Verma S; Mitropoulos F
    Curr Pharm Des; 2021; 27(8):1051-1060. PubMed ID: 33143620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SGLT2 inhibition and kidney protection.
    Nespoux J; Vallon V
    Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression.
    Leon SJ; Tangri N
    Curr Opin Nephrol Hypertens; 2022 Mar; 31(2):205-211. PubMed ID: 34954720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
    Diabetologia; 2018 Dec; 61(12):2461-2498. PubMed ID: 30288571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M
    Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
    [No Abstract]   [Full Text] [Related]  

  • 28. Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.
    Packer M
    Am J Med; 2020 Jul; 133(7):781-782. PubMed ID: 32061625
    [No Abstract]   [Full Text] [Related]  

  • 29. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
    Raschi E; Fadini GP; Diemberger I; Poluzzi E; De Ponti F
    Expert Opin Pharmacother; 2021 Apr; 22(5):647-650. PubMed ID: 33141609
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uric acid and the cardio-renal effects of SGLT2 inhibitors.
    Bailey CJ
    Diabetes Obes Metab; 2019 Jun; 21(6):1291-1298. PubMed ID: 30762288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DAPA-HF study: Are the benefits uniform across non-diabetic subgroups.
    Pareek A; Rajput R; Kumar Chopra H; Dharmadhikari S
    Indian Heart J; 2020; 72(5):469-470. PubMed ID: 33189217
    [No Abstract]   [Full Text] [Related]  

  • 33. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Vaduganathan M; Januzzi JL
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
    Thomson SC; Vallon V
    Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do we have enough evidence to support the use of SGLT2 inhibitors for MACE reduction in patients with advance kidney disease?
    Doshi R; Meghji Z; Kumar A; Shariff M; Adalja D
    Eur J Intern Med; 2019 Dec; 70():e25-e26. PubMed ID: 31685351
    [No Abstract]   [Full Text] [Related]  

  • 37. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
    Sano M
    J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
    Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF.
    Zhao LM; Ding LL; Zhan ZL; Qiu M
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1077-1078. PubMed ID: 34181127
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.